What's Happening in the Vitiligo Pipeline?

Pearl Grimes, MD, FAAD, a Dermatology Times® board member, and Seemal R. Desai, MD, FAAD, highlight the vitiligo pipeline.

The topic of the potential treatment ruxolitinib (Opzelura; Incyte), which the FDA granted Priority Review and has a Prescription Drug User Fee Act (PDUFA) target action date is April 18, 2022, as the first FDA approved therapy for vitiligo is brought up along with the costs of this treatment. Watch the full discussion below.